Alfagih, I.M.; Alfagih, M.; Almurshedi, A.; Aldosari, B.; Alquadeib, B.; Hajjar, B.; Almogheerah, S.; Alzahrani, R.
EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy. Pharmaceutics 2026, 18, 1179.
https://doi.org/10.3390/pharmaceutics18091179
AMA Style
Alfagih IM, Alfagih M, Almurshedi A, Aldosari B, Alquadeib B, Hajjar B, Almogheerah S, Alzahrani R.
EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy. Pharmaceutics. 2026; 18(9):1179.
https://doi.org/10.3390/pharmaceutics18091179
Chicago/Turabian Style
Alfagih, Iman M., Maryam Alfagih, Alanood Almurshedi, Basmah Aldosari, Bushra Alquadeib, Baraa Hajjar, Shahad Almogheerah, and Rund Alzahrani.
2026. "EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy" Pharmaceutics 18, no. 9: 1179.
https://doi.org/10.3390/pharmaceutics18091179
APA Style
Alfagih, I. M., Alfagih, M., Almurshedi, A., Aldosari, B., Alquadeib, B., Hajjar, B., Almogheerah, S., & Alzahrani, R.
(2026). EGFR-Targeted Nanoparticle Delivery of Osimertinib for Triple-Negative and Metastatic Breast Cancer Therapy. Pharmaceutics, 18(9), 1179.
https://doi.org/10.3390/pharmaceutics18091179
